Anthropic Opens Wet Lab for Physical Biology Experiments

Anthropic expands into physical drug research

Anthropic has established a wet lab in the San Francisco Bay Area to conduct physical biology experiments, marking a significant expansion beyond computational drug discovery work. The facility represents the AI company's push to develop treatments for rare diseases that traditional pharmaceutical companies have overlooked.

Eric Kauderer-Abrams, Anthropic's head of life sciences, confirmed the lab's existence in an interview with Reuters, which first reported the details. "We believe that to do biology, the final test is still and will be for a while in real lab work," he said. The company combines in-house laboratory work with external partnerships, similar to typical biotech operations.

A company spokesperson clarified that the lab is not specifically for drug discovery, though declined to provide additional details about its purpose.

Why it matters

Anthropic's move into physical laboratory work signals a broader ambition among AI companies to move beyond software into tangible scientific applications. The effort tests whether AI can meaningfully accelerate drug development for conditions previously considered "undruggable" — and whether the company can balance automation goals with the safety concerns that have dominated recent AI discourse. For pharmaceutical companies already partnering with Anthropic, the lab raises questions about potential competition and data protection.

Automation and robotics ambitions

The startup is working to enable its Claude AI system to direct robotic units in executing science experiments with limited human intervention, according to sources familiar with the matter. Anthropic maintains that human oversight remains essential for safety.

"We're in the very early innings of using AI to automate the execution of lab work," Kauderer-Abrams said, describing the area as having "potential to bring about meaningful acceleration in so many different processes."

The company launched the Model Hardware Standard in August to help AI systems operate laboratory equipment. Recent job postings have sought experts in protein and nucleic acid characterization, as well as a leader to scale procurement and operations.

Navigating competition and trust

Anthropic faces a delicate balance as it pursues its own drug programs while serving major pharmaceutical clients including Genentech, Bristol Myers Squibb, and Novo Nordisk. The company has established a boundary: it will not conduct clinical trials, focusing instead on preclinical work in areas that traditional companies find financially unattractive.

"We're not competing with pharma and biotech companies that make their business in bringing drugs to market," Kauderer-Abrams said.

The approach aims to address customer concerns that Anthropic might learn from their competing programs, even as the company walls off client data. Life sciences already represents one of Anthropic's largest investment areas by headcount and resources.

Personal mission amid broader tensions

For CEO Dario Amodei, the drug development effort is personal — a disease killed his father shortly before a cure emerged, he wrote in a recent essay. The timing is notable: in recent weeks, some Anthropic researchers have warned about AI extinction risks, and the company reported finding examples where its systems could potentially be used for biological weapons development.

Anthropic acquired Coefficient Bio for approximately $400 million in stock to build drug development tools, according to media reports confirmed by the company. The startup also added Novartis CEO Vas Narasimhan to its board and launched Claude Science software in June.

The precise diseases Anthropic is targeting and its progress remain unclear. Bringing a drug to market typically requires years of human trials — a challenge the company has not yet undertaken.

Reuters reporters Jeffrey Dastin and Michael Erman first reported these details.